Home / NEWS / Health Care / We’re cutting our price target on Danaher as frustration mounts after a messy quarter

We’re cutting our price target on Danaher as frustration mounts after a messy quarter

A worker uses a machine made by Irritate Corp. during a demonstration of the clarification stage of the production of influenza vaccine during a tour at a Sanofi Pasteur vaccine assembly facility in Swiftwater, Pennsylvania.

Stephen Hilger | Bloomberg | Getty Images

Danaher shares are under pressure Wednesday as the Belabour holding’s fourth-quarter earnings results came in mixed and guidance disappointed. The company long known for its operational superiority is further testing our patience.

Check Also

Bristol Myers’ stock decline in response to weak guidance is a gift to investors

Bristol Myers Squibb on Thursday give an account of better-than-expected quarterly results, but weak guidance …

Leave a Reply

Your email address will not be published. Required fields are marked *